Anxiety DisordersDepressive DisordersSchizophreniaPsilocybin

A multi-institutional investigation of psilocybin's effects on mouse behavior

In a coordinated five‑laboratory study of ~200 mice, psilocybin (2 mg/kg IP) produced robust, replicable acute behavioural effects — increased anxiety- and avoidance-related behaviour and reduced fear expression — but did not reproducibly produce persistent (24 h) anxiolytic, antidepressant, fear‑extinction or pro‑social effects. The multi‑institutional design therefore both delineates the reliable acute actions of psilocybin and provides a model for improving reproducibility in psychedelic research.

Authors

  • Boris Heifets
  • Lindsay Cameron

Published

Biorxiv
individual Study

Abstract

Studies reporting novel therapeutic effects of psychedelic drugs are rapidly emerging. However, the reproducibility and reliability of these findings could remain uncertain for years. Here, we implemented a multi-institutional collaborative approach to define the robust and replicable effects of the psychedelic drug psilocybin on mouse behavior. Five laboratories performed the same experiments to test the acute and persistent effects of psilocybin (2 mg/kg, IP) on various behaviors that psychedelics have been proposed to affect, including anxiety-related approach-avoidance, exploration, sociability, depression-related behaviors, fear extinction, and social reward learning. Through this coordinated approach, we found that psilocybin had several robust and replicable acute effects on mouse behavior, including increased anxiety- and avoidance-related behaviors and decreased fear expression. Surprisingly, however, we found that psilocybin did not have replicable effects 24 hours post psilocybin administration on reducing anxiety- and depression-like behaviors or facilitating fear extinction learning. Additionally, we were unable to observe psilocybin-induced alterations in social preference or social reward learning. Overall, our comprehensive characterization of psilocybin’s acute and persistent behavioral effects using ∼200 total male and female mice per experiment spread across five independent labs demonstrates with unique certainty several acute drug effects and suggests that psilocybin’s persistent effects in mice may be more modest and inconsistent than previously suggested. We believe this unusual multi-laboratory, highly coordinated research effort serves as a model for facilitating the generation of replicable results and consequently will reduce efforts based on unreliable and spurious results.

Available with Blossom Pro

Research Summary of 'A multi-institutional investigation of psilocybin's effects on mouse behavior'

Introduction

After decades of limited investigation, interest in psychedelic drugs has resurged because single or few doses of compounds such as psilocybin, MDMA, LSD and ibogaine appear to produce rapid and sometimes enduring therapeutic effects across several neuropsychiatric conditions. Earlier preclinical and clinical reports have been inconsistent: some studies report antidepressant- or anxiolytic-like effects in rodents and humans, while others find null or contradictory results. These inconsistencies raise concerns about robustness and replicability of reported psychedelic effects and about how well results from single laboratories generalise. To address that gap, Lu and colleagues implemented a coordinated, multi-institutional approach to identify behavioral effects of psilocybin in mice that are robust and replicable across laboratories. The consortium aligned on strain (C57BL/6J), age range, sex inclusion, dose (2 mg/kg IP), core experimental protocols and timepoints, and tested a battery of assays probing acute (minutes after dosing) and persistent (around 24 hours after dosing) effects on head twitch response, anxiety-related approach–avoidance and exploration, sociability, depression-related passive coping, cued fear expression and extinction, and social reward learning. The study aimed to determine which psilocybin effects are reliably observed across independent labs and which are small, variable, or absent under these standardised conditions.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Pro members can view the original manuscript directly in the browser.

Study Details

  • Study Type
    individual
  • Journal
  • Compound
  • Topics
  • Authors
  • APA Citation

    Lu, O. D., White, K., Raymond, K., Liu, C., Klein, A. S., Green, N., Vaillancourt, S., Gallagher, A., Shindy, L., Li, A., Wallquist, K., Li, R., Zou, M., Casey, A. B., Cameron, L. P., Pomrenze, M. B., Sohal, V., Kheirbek, M. A., Gomez, A. M., . . . Malenka, R. (2025). A multi-institutional investigation of psilocybin's effects on mouse behavior. https://doi.org/10.1101/2025.04.08.647810

References (23)

Papers cited by this study that are also in Blossom

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)

1174 cited
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial

Raison, C. L., Sanacora, G., Woolley, J. D. et al. · JAMA (2023)

375 cited
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · New England Journal of Medicine (2022)

656 cited
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial

Mitchell, J., Ot’alora G, M., van der Kolk, B. et al. · Nature Medicine (2023)

399 cited
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases

Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)

594 cited
Magnesium-ibogaine therapy in veterans with traumatic brain injuries

Cherian, K. N., Keynan, J. N., Anker, L. et al. · Nature Medicine (2024)

68 cited
Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study

Frampton, C. M., Yazar-Klosinski, B., Nollar, G. E. · The American Journal of Drug and Alcohol Abuse (2017)

122 cited
Trial of Psilocybin versus Escitalopram for Depression

Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)

927 cited
Show all 23 references
Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat

Jefsen, O., Højgaard, K., Christiansen, S. L. et al. · Acta Neuropsychiatrica (2019)

60 cited
5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines

Cameron, L. P., Patel, S. D., Vargas, M. V. et al. · ACS Chemical Neuroscience (2023)

86 cited
The pharmacology of psilocybin

Passie, T., Seifert, J., Schneider, U. et al. · Addiction Biology (2002)

Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice

Fadahunsi, N., Lund, J., Breum, A. W. et al. · Translational Psychiatry (2022)

41 cited
Psychedelics reopen the social reward learning critical period

Nardou, R., Sawyer, E., Song, Y. J. et al. · Nature (2023)

Oxytocin-dependent reopening of a social reward learning critical period with MDMA

Nardou, R., Lewis, E. M., Rothhaas, R. et al. · Nature (2019)

A non-hallucinogenic psychedelic analogue with therapeutic potential

Cameron, L. P., Tombari, R. J., Lu, J. et al. · Nature (2020)

70 cited
Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors

Vargas, M. V., Dunlap, L. E., Dong, C. et al. · Science (2023)

330 cited
Psychedelic-inspired drug discovery using an engineered biosensor

Dong, C., Ly, C., Dunlap, L. E. et al. · Cell (2021)

Psychedelics promote plasticity by directly binding to BDNF receptor TrkB

Moliner, R., Girych, M., Brunello, C. A. et al. · Nature Neuroscience (2023)

Cited By (1)

Papers in Blossom that reference this study

Psychedelic medicine: mechanisms, evidence, and translation to practice

Jacobs, E., Zahid, Z., Hinkle, J. et al. · BMJ (2026)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

A multi-institutional investigation of... — Research Summary & Context | Blossom